Diversity in Trials

Jonathan discusses the critical need for increased diversity in clinical trials, particularly in Alzheimer's research. He emphasizes that understanding disease mechanics requires reflecting the populations most affected, rather than merely mirroring census data. With FDA scrutiny on the horizon, there's hope for more rigorous guidelines to ensure equitable representation in drug studies.